Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of acute undifferentiated leukemia with a Ph1-chromosome and a typical translocation t(9;22) is reported in a 54-year-old female with Hodgkin's disease. The interval from diagnosis of Hodgkin's disease to the development of acute leukemia was 19 months. Treatment of Hodgkin's disease consisted of combined cytotoxic therapy including irradiation and chemotherapy. Detection of Ph1-chromosome in undifferentiated blasts supports the suggestion of leukemogenic chromosomal aberration within uncommitted hemopoietic cells.
 ...
PMID:Ph1-positive acute leukemia in a patient with Hodgkin's disease treated by irradiation and chemotherapy. 373 21

Acute nonlymphocytic leukemia is a recognized complication of combined chemotherapy and radiation treatment of patients with Hodgkin's disease. Previous studies have suggested that the risk of leukemia in these patients increases with time after treatment. We analyzed the occurrence of second neoplasms among 192 patients with Hodgkin's disease who were followed for a median of over 15 years. We originally planned to identify prospectively the morphologic changes in bone marrow that precede the development of acute leukemia. All 63 patients consenting to bone marrow aspiration had normal marrow morphology, and no case of acute leukemia occurred more than 11 years after treatment. Actuarial analysis revealed that the peak onset of leukemia-related complications was between three and nine years after first treatment. We conclude that there appears to be a period of increased risk in patients treated with chemotherapy and radiation, after which the risk of secondary leukemia decreases. Patients surviving for more than 11 years after treatment appear to be at no increased risk of acute leukemia.
 ...
PMID:Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. 382 9

The authors report the use of the cytostatic drug cytosar in the control of herpetic complications in patients with acute leukemia and lymphogranulomatosis. A distinct effect was obtained as a result of intravenous drip of cytosar in a dose of 0.03-0.05 g for 2 days. It is desirable that cytosar therapy may be instituted within the first days of the development of herpetic infection.
 ...
PMID:[Use of cytosar (cytosine arabinoside) in the control of herpetic complications in patients with acute leukemia and lymphogranulomatosis]. 386 Sep 98

Marrow transplantation is effective treatment for a number of hematological diseases in patients under the age of 50 who have an HLA-identical sibling donor. It is successful in the treatment of aplastic anemia with 70-85% long-term survival. It offers 10-30% apparent cures for patients with acute leukemia who have relapsed at least once, and for those with chronic myelocytic leukemia in blast crisis. Although still somewhat controversial, it appears to be the treatment of choice for patients with acute nonlymphoblastic leukemia in first chemotherapy induced remission, and for those with chronic myelogenous leukemia in the chronic phase since approximately 50-60% of these patients experience long-term, disease-free survival. Patients with acute lymphoblastic leukemia grafted in second or subsequent remission may expect a 30% "cure" of their disease. Marrow grafting is the only effective treatment for many patients with inherited immunologic deficiencies and certain genetic storage diseases. Cures of congenital Fanconi's anemia, Blackfan-Diamond anemia, osteopetrosis, paroxysmal nocturnal hemoglobinuria and thalassemia major have been achieved. Marrow transplantation is being explored for the therapy of patients with lymphoma, Hodgkin's disease, preleukemia, multiple myeloma, hairy cell leukemia, small cell lung cancer, testicular cancer, ovarian cancer and neuroblastoma. Marrow transplantation has been limited by the fact that many patients do not have HLA-identical siblings and very few have monozygotic twins. More recently, marrow transplants from HLA-nonidentical family members and even from unrelated donors have been successfully explored.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Marrow transplantation: the Seattle experience. 391 47

A Phase II clinical trial of NK 171 (Etoposide), a semisynthetic podophyllotoxin, was undertaken in 56 patients with advanced malignant lymphoma and 36 patients with acute leukemia. The dosage of NK 171 was 110-130 mg/m2 day p.o. or 80-100 mg/m2 day i.v. for 5 consecutive days. Of the 92 patients, 23.9% obtained a complete or partial remission. By tumor type, good responses were obtained in non-Hodgkin's lymphoma (34%, 17/50), Hodgkin's disease (25%, 1/4), AML (21.4%, 3/14), and CML-BC (25%, 1/4). Side effects included leukopenia (78.4%), alopecia (62.0%), anorexia (40.2%), nausea (30.4%) thrombocytopenia (25.6%) and fever (16.3%). These results demonstrated NK 171 to be an effective agent against malignant lymphoma and acute myeloblastic leukemia.
 ...
PMID:[Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies]. 395 73

Four patients with chromosome #12 rearrangement at the p11 level are described. One had acute promyelocytic leukemia, one had myelofibrosis evoluting to acute undifferentiated leukemia, one had acute nonlymphoid leukemia (ANLL) secondary to Hodgkin's disease, and another had acute leukemia recurring after allogeneic bone marrow transplantation. This chromosome abnormality was always associated with other karyotypic aberrations, probably as a secondary event. Possible correlations with recent findings in oncogene research are discussed.
 ...
PMID:Chromosome 12 rearrangement with breakage at the p11 level in hematologic disorders: report of four cases. 397 22

Tetanus toxin (TT) was used as a diagnostic marker for human neuroblastoma (NB) cells. TT binding sites visualized by TT and FITC-conjugated anti-TT antibodies were present on NB cells from all 13 cases studied comprising Stages II, III, IV, IVS and histologic grades 1 through 3. NB cells from both bone marrow aspirates and tumor biopsies as well as cultured NB cells were TT-positive. Diagnosis of NB was further ascertained by electron microscopy, cell culture, and quantitative determinations of catecholamines in tumor material. Only electron microscopic diagnoses had an accuracy comparable to that of TT labeling. None of the non-NB tumors (Ewing's sarcoma, acute lymphatic and myeloic leukemia, acute monocyte leukemia, chronic myeloic leukemia, Hodgkin's disease, oat cell carcinoma of the lung, pheochromocytoma), except for the pheochromocytoma, were found to bind TT specifically. These results suggest that TT may be profitably employed as a diagnostic marker of human NB cells. The advantages of the methods are its high discriminative capacity against non-NB cells and rapid applicability.
 ...
PMID:Tetanus toxin labeling as a novel rapid and highly specific tool in human neuroblastoma differential diagnosis. 400 7

Activity of adenosine deaminase (EC 3.5.4.4) was studied in thrombocytes of donors and patients with various hematological diseases. The enzymatic activity was decreased in acute leukemia, chronic myeloleukemia, chronic leukemia and blast transformation myeloma, microspherocytic and hypoplastic anemias. Variable level of the activity was observed in chronic lympholeukemia and non-Hodgkin disease. In all the diseases studied functions of thrombocytes were altered after treatment with various aggregating agents (ADP, thrombin, collagen, adrenaline, ristomycin).
 ...
PMID:[Platelet adenosine desaminase in various hematological diseases]. 406 12

In an occupational mortality analysis of 486,000 adult male death records filed in Washington State in the years 1950-1982, leukemia and the non-Hodgkin's lymphomas show increased proportionate mortality ratios (PMRs) in workers employed in occupations with intuitive exposures to electromagnetic fields. Nine occupations of 219 were considered to have electric or magnetic field exposures. These were: electrical and electronic technicians, radio and telegraph operators, radio and television repairmen, telephone and power linemen, power station operators, welders, aluminum reduction workers, motion picture projectionists and electricians. There were 12,714 total deaths in these occupations. Eight of the nine occupations had PMR increases for leukemia [International Classification of Diseases (ICD), seventh revision 204] and seven of the nine occupations had PMR increases for the other lymphoma category (7th ICD 200.2, 202). The highest PMRs were seen for acute leukemia: (67 deaths observed, 41 deaths expected; PMR 162), and in the other lymphomas (51 deaths observed, 31 deaths expected; PMR 164). No increase in mortality was seen for Hodgkin's disease or multiple myeloma. These findings offer some support for the hypothesis that electric and magnetic fields may be carcinogenic.
 ...
PMID:Mortality in workers exposed to electromagnetic fields. 408 33

Four cases of acute leukemia occurring in patients with Hodgkin's disease are described. The literature on the association of these two diseases is reviewed. Acute myeloid or undifferentiated leukemias appear to be, at least in part, a complication affecting long-term survivors of Hodgkin's disease. Reed Sternberg cell leukemia is an unusual form of Hodgkin's disease and may be associated with a poor prognosis. The cytology and cytochemistry of Reed Sternberg cells are briefly discussed.
 ...
PMID:Hodgkin's disease and leukemia. 450 67


<< Previous 1 2 3 4 5 6 7 8 9 10